Clarity Pharmaceuticals Secures Long-Term Copper-64 Supply from Nusano to Bolster Cancer Therapy Pipeline

Highlights

• Clarity inks multi-year copper-64 supply deal with Nusano
• Nusano’s facility supports large-scale isotope production
• Agreement strengthens pipeline for oncology diagnostics and therapies

Clarity Pharmaceuticals (ASX:CU6) has announced the signing of a strategic, commercial-scale Supply Agreement with US-based isotope producer Nusano, Inc. The agreement covers the provision of copper-64, a key medical isotope used in the development of advanced cancer diagnostics and therapies.

The partnership marks a significant milestone in Clarity’s mission to expand its radiopharmaceutical capabilities and ensure a consistent supply of critical isotopes across its theranostic pipeline. Copper-64 plays an essential role in the company’s targeted imaging and therapeutic programs, and this agreement is expected to enhance the scalability and reliability of those programs moving forward.

Nusano’s production facility, located in West Valley City, Utah, spans 190,000 square feet and is equipped to produce over 1,000 curies (Ci) of copper-64 daily. This translates to more than 18,000 individual patient doses, each with a 48-hour shelf-life. The high-output capacity is designed to meet the demands of multiple large-scale oncology indications, providing a robust foundation for the commercial distribution of copper-64 products.

In addition to copper-64, Nusano is preparing to expand its production capabilities to include other medical isotopes such as copper-67 and actinium-225. These isotopes are essential components in Clarity’s ongoing development of theranostic agents, which combine diagnostic imaging with targeted radiotherapy to improve treatment outcomes in oncology. Production of these isotopes is anticipated to begin between 2025 and 2026.

The newly signed agreement takes effect on April 16, 2025, and is set for an initial term of three years. It includes provisions for automatic renewal every two years thereafter, ensuring long-term stability and flexibility. Standard industry termination clauses have also been incorporated.

Clarity’s Executive Chairperson, Dr Alan Taylor, emphasized the strategic value of this supply partnership, noting that it enhances the company's existing network of US-based copper-64 sources. The collaboration is designed to secure a stable supply chain, mitigating risks of isotope shortages and supporting Clarity’s broader commercialization plans.

By aligning with a high-capacity supplier like Nusano, Clarity (CU6) reinforces its position as a key player in the growing field of radiopharmaceuticals, with a clear focus on scalable, patient-centric oncology solutions.